Quest Diagnostics EBITDA 2010-2024 | DGX

Quest Diagnostics EBITDA for the quarter ending December 31, 2024 was $0.455B, a 0.44% increase year-over-year.

  • Quest Diagnostics 2024 EBITDA was 1.839B, a 8.11% increase from 2023.
  • Quest Diagnostics 2023 EBITDA was 1.701B, a 8.79% decline from 2022.
  • Quest Diagnostics 2022 EBITDA was 1.865B, a 33.13% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Quest Diagnostics EBITDA 2010-2024 | DGX

  • Quest Diagnostics 2024 EBITDA was 1.839B, a 8.11% increase from 2023.
  • Quest Diagnostics 2023 EBITDA was 1.701B, a 8.79% decline from 2022.
  • Quest Diagnostics 2022 EBITDA was 1.865B, a 33.13% decline from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Fresenius SE (FSNUY)$21.5B
DaVita (DVA)$12.4B
Encompass Health (EHC)$10.2B
Chemed (CHE)$8.4B
Elanco Animal Health (ELAN)$5.6B
Option Care Health (OPCH)$5.5B
RadNet (RDNT)$4.8B
LifeStance Health (LFST)$3.1B
Amedisys (AMED)$3B
Astrana Health (ASTH)$2.2B
Addus HomeCare (ADUS)$2.1B
U.S Physical Therapy (USPH)$1.3B
Aveanna Healthcare Holdings (AVAH)$968M
Pennant (PNTG)$927M
Atai Life Sciences (ATAI)$351M
Bioqual (BIOQ)$54M
Daxor (DXR)$35M
Ontrak (OTRK)$7M
MEDIROM Healthcare Technologies (MRM)$4M
IMAC Holdings (BACK)$1M
Psychemedics (PMD)$0M